Health & Diseases

Mast Cell Tumors in Dogs: Symptoms, Grading, and Treatment

The mast cell tumor (MCT, mastocytoma) is the most common cutaneous tumor in dogs, accounting for approximately 20% of all canine skin tumors. It originates from mast cells—immune cells found in the skin, intestines, and other tissues that release histamine, heparin, and other mediators when irritated. Mast cell tumors are known as “the great imitator”—they can clinically resemble benign lipomas, cysts, or inflammatory lesions.

Mast Cell Tumors in Dogs: Symptoms, Grading, and Treatment

What is a mast cell tumor in dogs?

The mast cell tumor (MCT, mastocytoma) is the most common cutaneous tumor in dogs, accounting for approximately 20% of all skin tumors. It arises from mast cells—immune cells found in the skin, intestines, and other tissues that release histamine, heparin, and other mediators when irritated. Mast cell tumors are known as “the great imitators”—they can clinically resemble benign lipomas, cysts, or inflammatory changes.

Any new skin lesion in a dog should undergo a fine-needle aspiration biopsy before it is deemed benign.

Background + Scientific Context

Kiupel et al. (2011, Veterinary Pathology, https://pubmed.ncbi.nlm.nih.gov/20930199/) developed the current 2-tier grading system for canine mast cell tumors: The old 3-tier system (Patnaik Grade 1–3) showed poor interobserver agreement. The new 2-tier system classifies tumors into high-grade and low-grade based on defined histological criteria (mitotic rate, nuclear polymorphism, multinucleated cells, atypical mitoses, nuclear features). High-grade MCT has a significantly poorer prognosis than low-grade MCT—1-year survival rate: low grade > 80%; high grade < 30%. Grading requires histological examination following surgical excision—fine-needle aspiration (FNA) can cytologically confirm MCT but cannot assign a grade.

London et al. (2009, Clinical Cancer Research, https://pubmed.ncbi.nlm.nih.gov/19470739/) demonstrated the efficacy of toceranib (Palladia) in MCTs with KIT mutations: Toceranib is an oral tyrosine kinase inhibitor (TKI) that inhibits KIT mutations leading to uncontrolled mast cell proliferation. In the multicenter RCT, toceranib demonstrated significantly higher remission rates compared to placebo in patients with inoperable MCTs. A KIT mutation test (exon 11 analysis) should be performed prior to TKI use—patients with the mutation respond better.

Ettinger et al. (2017, *Textbook of Veterinary Internal Medicine*) describe the diagnostic approach, staging, and treatment algorithm: FNA cytology is highly diagnostic for MCT—the characteristic granular granules of mast cells are unmistakable. Pre-treatment: Staging with local lymph node FNA, abdominal ultrasound (liver, spleen, intestines), and bone marrow aspiration if necessary. Surgical excision with a wide safety margin (2 cm laterally + 1 fascial layer deep) is the primary treatment. Positive resection margins (R1/R2) in low-grade MCT: re-resection or radiation therapy. High-grade MCT: adjuvant chemotherapy (vinblastine + prednisolone regimen) recommended.

Vitomalia-Position

Any new skin lesion in a dog is considered a malignant tumor until proven otherwise. Fine-needle aspiration (FNA) is inexpensive and quick—it prevents unpleasant surprises after weeks of waiting. Early biopsy, early surgery, and a wide surgical margin offer the best chance of a cure.

When does a mast cell tumor become a concern?

  • New skin lesion of unknown origin: Fine-needle aspiration (FNA) before any treatment
  • A swelling, tingling, or changing skin lesion: Darier's sign (mast cell degranulation caused by irritation of the lesion)
  • Breeds at increased risk: Labrador, Golden Retriever, Boxer, Staffordshire Bull Terrier
  • After excision without histology: always send a sample
  • Systemic symptoms (vomiting, stomach ulcer, frequent scratching): Investigate MCT mediator effects

Practical application

Step-by-Step Guide to Mast Cell Tumor Diagnosis:

Step Action Goal
1 Fine-needle aspiration of the lesion Cytological confirmation of MCT
2 Lymph node fine-needle aspiration Local staging
3 Abdominal ultrasound Systemic Staging
4 Surgical excision + histology Grading (High/Low), Margin Assessment
5 Mutation Test Kit Indications for TKI (Toceranib)
6 Adjuvant Therapy In cases of high-grade tumors, positive margins, or metastases

Grading and Prognosis: - Low grade: 1-year survival rate > 80%; complete surgical excision is often curative - High grade: median survival time without treatment is weeks; with chemotherapy, several months - Positive KIT mutation: better response to toceranib (Palladia)

Common Mistakes & Myths

  • “The lump has been there for years—it’s nothing to worry about.” Mast cell tumors can remain stable for years, even decades, and then suddenly become aggressive. Stability does not rule out malignancy.
  • “I’ll just have the nodule removed without performing a biopsy first.” Without a preoperative diagnosis, the surgical plan will be incorrect—MCTs require wide resection margins (2 cm), which are often not planned for without a prior diagnosis. FNA is always the first step.
  • “A mast cell tumor is always cancer—the dog won’t survive it.” Low-grade MCTs are often curable after complete excision. The diagnosis alone does not determine the prognosis—grading and staging are the deciding factors.

Current State of Research (2026)

The Kiupel 2-tier grading system is the standard in veterinary oncology. Toceranib (Palladia) is the first oral anticancer drug approved for dogs and is part of the standard of care for inoperable or KIT-mutated MCTs. Immunotherapeutic approaches and new TKIs (imatinib, masitinib) are being investigated for MCTs. Liquid biopsy (circulating tumor DNA) is an emerging area of research for MCT monitoring.

Frequently Asked Questions

How can I tell if my dog has a mast cell tumor?

Mast cell tumors can look like almost any skin lesion—ranging from small, firm nodules to soft swellings or red patches. Darier’s sign (enlargement upon rubbing or stimulation) is suggestive but not specific. Any new skin lesion should be evaluated via fine-needle aspiration (FNA).

What is the prognosis for a mast cell tumor in dogs?

Depending on the grade: Low-grade MCTs have a 1-year survival rate of over 80% following complete resection. High-grade MCTs without treatment have a survival time of a few weeks to months; with adjuvant chemotherapy, survival ranges from several months to years. A KIT mutation improves the response to toceranib.

Does a mast cell tumor always require surgery?

Surgical excision is the preferred treatment—especially for solitary, resectable low-grade tumors. For inoperable tumors or high-grade MCTs, a combination of radiation therapy and chemotherapy may be used. Toceranib (Palladia) is approved for inoperable or metastatic MCTs.

Related terms

Sources & Further Reading

  1. Kiupel, M., Webster, J. D., Bailey, K. L., Best, S., DeLay, J., Detrisac, C. J., et al. (2011). Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors. Veterinary Pathology, 48(1), 147–155. https://pubmed.ncbi.nlm.nih.gov/20930199/

  2. London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., et al. (2009). Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654) for the treatment of dogs with recurrent mast cell tumor. Clinical Cancer Research, 15(11), 3856–3865. https://pubmed.ncbi.nlm.nih.gov/19470739/

  3. Ettinger, S. J., Feldman, E. C., & Côté, E. (Eds.) (2017). Textbook of Veterinary Internal Medicine (8th ed.). Saunders. ISBN 9780323312110.

Wissenschaftliche Einordnung

Kiupel et al. (2011, Veterinary Pathology, https://pubmed.ncbi.nlm.nih.gov/20930199/) developed the current 2-tier grading system for canine mast cell tumors: The old 3-tier system (Patnaik Grade 1–3) showed poor interobserver agreement. The new 2-tier system classifies tumors into high grade and low grade based on defined histological criteria (mitotic count, nuclear pleomorphism, multinucleated cells, atypical mitoses, nuclear characteristics). High-grade MCTs have a significantly worse prognosis than low-grade MCTs — 1-year survival rate for low grade > 80%; high grade < 30%. Grading requires histological examination after surgical excision — fine needle aspirate (FNA) can cytologically confirm MCT but cannot assign a grade.

London et al. (2009, Clinical Cancer Research, https://pubmed.ncbi.nlm.nih.gov/19470739/) demonstrated the efficacy of toceranib (Palladia) in MCTs with KIT mutation: Toceranib is an oral tyrosine kinase inhibitor (TKI) that inhibits KIT mutations, which lead to uncontrolled mast cell division. In the multicenter RCT, toceranib showed significantly higher remission rates compared to placebo in inoperable MCTs. Before TKI use, KIT mutation testing (Exon 11 analysis) should be performed — mutation carriers respond better.

Ettinger et al. (2017, Textbook of Veterinary Internal Medicine) describe diagnosis, staging, and treatment algorithms: FNA cytology is highly diagnostic for MCTs — the typical granular mast cell granules are unmistakable. Before treatment: Staging with local lymph node FNA, abdominal ultrasound (liver, spleen, intestine), and bone marrow aspirate if necessary. Surgical excision with wide surgical margins (2 cm lateral + 1 fascial plane deep) is the primary therapy. Positive resection margins (R1/R2) in low-grade MCTs: Re-excision or radiation therapy. High-grade MCTs: Adjuvant chemotherapy (vinblastine + prednisolone protocol) is recommended.